Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Biogaia Ag (BIOG B) SER B NPV

Sell:422.50 SEK Buy:425.50 SEK Change: 1.50 SEK (0.35%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Sell:422.50 SEK
Buy:425.50 SEK
Change: 1.50 SEK (0.35%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
Sell:422.50 SEK
Buy:425.50 SEK
Change: 1.50 SEK (0.35%)
Market closed |  Prices as at close on 5 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.

Contact details

Kungsbroplan 3
112 27
+46 (8) 55529300

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
8.27 billion SEK
Shares in issue:
20.20 million
Stockholm Stock Exchange
Swedish Krona

Key personnel

  • Peter Rothschild
    Chairman of the Board
  • Isabelle Ducellier
    President, Chief Executive Officer
  • David Dangoor
    Independent Vice Chairman of the Board
  • Alexander Kotsinas
    Chief Financial Officer, Executive Vice President
  • Urban Strindlov
    Executive Vice President - Sales
  • Ulrika Kohler
    Executive Vice President of Marketing
  • Sebastian Schroder
    Executive Vice President - Business and Product Development
  • Marika Isberg
    Vice President, General Counsel
  • Angelika Kjelldorff
    Vice President Human Resources
  • Gianfranco Grompone
    Vice President - Discovery and Research

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.